The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 3 of the 7 sources its claims cite were checked for support.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Open accessAbstract
BACKGROUND: Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. METHODS: We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. RESULTS: white cells) (P<0.001). The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%), lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%). CONCLUSIONS: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 of 7 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The phase 3 Southwest Oncology Group (SWOG) S0777 trial of lenalidomide plus dexamethasone with or without bortezomib in patients with newly diagnosed myeloma for whom immediate autologous stem-cell transplantation was not indicated showed that the triplet combination resulted in longer progression-free survival (median, 41 months vs. 29 months; hazard ratio, 0.74), including among patients who”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
- Also stated in: § CONCLUSIONS · boosted
“these findings established the regimen of lenalidomide and dexamethasone as standard of care.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Abstract > BACKGROUND
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [17] source
The Introduction calls lenalidomide plus dexamethasone one of the standards of care for newly diagnosed multiple myeloma and specifically lists it as a treatment option for patients ineligible for autologous stem-cell transplant. This directly supports the citing sentence. (LLM, conf=0.94)
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § CONCLUSIONS · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in the CASTOR and POLLUX trials, among patients with relapsed or refractory multiple myeloma who had a high-risk cytogenetic profile, substantial benefits with respect to progression-free survival and minimal residual disease with daratumumab plus standard-of-care regimens were observed after a longer follow-up period.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Efficacy section (p. 9) says the longer-follow-up POLLUX progression-free survival benefit was maintained across cytogenetic-risk subgroups, and the Discussion (p. 11) reports higher MRD-negativity rates overall. It does not establish an MRD benefit specifically in high-risk patients. Its CASTOR comparison (Discussion, p. 11) concerns patients with one prior therapy, not the high-risk cytogenetic subgroup. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [25] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prespecified subgroup analyses of progression-free survival confirmed the superiority of the daratumumab regimen over the control regimen across all subgroups, except in the subgroup of patients who had hepatic impairment at baseline (Fig. 2).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The progression-free survival benefit was maintained among patients 75 years of age or older (hazard ratio, 0.63; 95% CI, 0.44 to 0.92).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the patients who had a response (partial response or better), 80.3% (95% CI, 75.1 to 84.5) in the daratumumab group and 65.7% (95% CI, 58.6 to 71.8) in the control group sustained the response for 30 months.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab plus lenalidomide and dexamethasone was associated with a higher incidence of neutropenia and infections.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negative status for minimal residual disease was associated with longer progression-free survival than positive status, regardless of the trial treatment (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with an overall response was 92.9% in the daratumumab group and 81.3% in the control group (P<0.001).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of infections of any grade was 86.3% in the daratumumab group and 73.4% in the control group; the incidence of grade 3 or 4 infections was 32.1% in the daratumumab group and 23.3% in the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 7
- Probably not a substantial claim. 3
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our trial population was notably older; 99% of the patients were 65 years of age or older, and 44% were 75 years of age or older.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached in the daratumumab group and was 31.9 months (95% CI, 28.9 to not reached) in the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Results > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this trial involving patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, the addition of daratumumab to lenalidomide and dexamethasone resulted in significantly longer progression-free survival, a higher response rate, an increased depth of response, and a longer duration of response than lenalidomide and dexamethasone alone.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was stratified according to International Staging System disease stage (I vs. II vs. III, with higher stages indicating more severe disease) (see Table S1 in the Supplementary Appendix for details on the staging criteria), geographic region (North America vs. other), and age (<75 vs. ≥75 years).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > RANDOMIZATION AND TREATMENT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We estimated that a sample of 730 patients would provide the trial with 80% power to detect a risk of disease progression or death that was 25% lower with daratumumab plus lenalidomide and dexamethasone than with lenalidomide and dexamethasone alone, using a log-rank test at a two-sided alpha level of 0.05.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary analysis was performed in the intention-to-treat population, which included all patients who underwent randomization.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Methods > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients who discontinued treatment because of these adverse events was low in our trial and was consistent with the safety profile observed in the POLLUX and ALCYONE trials, the latter of which represents a similar population of patients with newly diagnosed myeloma who were ineligible for stem-cell transplantation.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group).”
- Also stated in: § PATIENTS AND TREATMENT · plain
“A total of 737 patients were randomly assigned — 368 to the daratumumab group and 369 to the control group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Abstract > METHODS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § PATIENTS AND TREATMENT · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although patients in the daratumumab group received treatment for a longer period of time, they received less lenalidomide than the control group, possibly owing to a higher incidence of adverse events that led to dose discontinuations or dose modifications in this group.”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
§ Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma > Discussion
What the sources say
- Not checked — no full text of the sourcecites [5] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DRd is approved for patients with newly diagnosed myeloma based on the results of an international multicenter randomized trial which showed benefit over lenalidomide plus dexamethasone (Rd).97”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Meta-analyses suggest that indefinite maintenance therapy is superior in terms of survival outcomes36”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [36]
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · cited 2×
“‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”
BackgroundMethodSelf-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,013
Garderet, L., Morris, C., Beksaç, M., Gahrton, G., Schönland, S. O., Yakoub‐Agha, I., & Hayden, P. J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.016 · Cited by 11
Dávila, J., González‐Calle, V., Escalante, F., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18182 · Cited by 11
Rixecker, T. M., Lepper, P. M., Mang, S., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0152 · Cited by 11
Štork, M., Špıčka, I., Radocha, J., Minařík, J., Jelı́nek, T., Jungová, A., Pavlíček, P., Pospíšilová, L., Sedlák, F., Štraub, J., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05188-4 · Cited by 11
Ramasamy, K., Dhanasiri, S., Thom, H. H. Z., Buchanan, V., Robinson, S. K., D’Souza, V., & Weisel, K. C. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1683736 · Cited by 11
“65) NR MAIA [25] Dþ Rd (368) vs Rd (369) 0.”
MethodResultInfluentialSelf-citationCurrent developments in the combination therapy of relapsed/refractory multiple myeloma
Maples, K. T., Joseph, N. S., & Harvey, R. D. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1828071 · Cited by 11
Ninkovic, S., & Quach, H. (2020) · Cancers · doi:10.3390/cancers12113488 · Cited by 9
“Finally, continuous therapy with daratumumab, has also been explored in the TNE setting with evidence of improved depth of response both as monotherapy (ALCYONE), and in combination with lenalidomide (MAIA) [67,68].”
BackgroundInfluentialSelf-citationCurrent Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
Marneni, N., & Chakraborty, R. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00631-7 · Cited by 12
Gay, F., Günther, A., Offidani, M., Engelhardt, M. M., Salvini, M., Montefusco, V., Patriarca, F. F., Aquino, S., Pönisch, W., Spada, S., et al. (2021) · Cancer · doi:10.1002/cncr.33647 · Cited by 11
Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H., Merz, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0976-9 · Cited by 11
Self-citationWhy Immunotherapy Fails in Multiple Myeloma
Rodríguez‐Lobato, L. G., Oliver‐Caldés, A., Moreno, D. F., de Larrea, C. F., & Bladé, J. (2020) · Hemato · doi:10.3390/hemato2010001 · Cited by 11
“and prednisone [67] or lenalidomide and dexamethasone [68]).”
Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
Richter, J. R., Pan, D., Salinardi, T. C., & Rice, M. S. (2023) · eJHaem · doi:10.1002/jha2.739 · Cited by 9
Treatment of multiple myeloma with selinexor: a review
Huang, Q., Zhao, R., Xu, L., Hao, X., & Tao, S. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207231219442 · Cited by 12
Martín‐Sánchez, E., Blanco, L., Kim, P., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013212 · Cited by 10
Paul, B. A., Anwer, F., Raza, S., Mammadzadeh, A., Khasawneh, B., Shatnawi, S., McGuirk, J. P., Ahmed, N., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2024) · Cancers · doi:10.3390/cancers16172938 · Cited by 10
“Several other anti-myeloma therapies have similarly been added to standard-of-care doublets and triplet induction therapies in both transplant-eligible and transplant-ineligible NDMM [15,21,22,31,34–37].”
BackgroundYee, A. J., Laubach, J. P., Campagnaro, E. L., Lipe, B. C., Nadeem, O., Friedman, R. S., Cole, C. E., O’Donnell, E., Bianchi, G., Branagan, A. R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014717 · Cited by 10
“23 However, data on the ef fi cacy of elotuzumab after anti-CD38 antibody treatment are limited.”
Self-citationKawaji‐Kanayama, Y., Kobayashi, T., Muramatsu, A., Uchiyama, H., Sasaki, N., Uoshima, N., Nakao, M., Takahashi, R., Shimura, K., Kaneko, H., et al. (2021) · Cancer Reports · doi:10.1002/cnr2.1476 · Cited by 10
Luo, M., Zhu, P., Nnane, I. P., Xiong, Y., Merlini, G., Comenzo, R. L., Kastritis, E., Wechalekar, A. D., Weiss, B. M., Tran, N., et al. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1994 · Cited by 10
Gordan, L., Marks, S. M., Xue, M., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-1072 · Cited by 10
Narsipur, N., Bulla, S., Yoo, C., Do, B., Tran, K., Gu, D., Zhong, L., & Wilson, L. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.12.1691 · Cited by 11
Djebbari, F., Rampotas, A., Panitsas, F. P., Lim, W. Y., Lees, C., Tsagkaraki, I., Gomes, A. R., Prideaux, S., Chen, L., Prodger, C. F., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262388 · Cited by 10
“The myeloma treatment landscape for TNE NDMM patients is shifting towards the continuous therapy (CT) strategy, such as continuous lenalidomide and dexamethasone as per FIRST trial [11], continuous daratumumab with lenalidomide and dexamethasone as per MAIA trial [12], and continuous daratumumab with bortezomib, melph…”
MethodGeerts, P. A. F., Eijsink, J. F. H., Moser, A., ter Horst, P. G. J., Boersma, C., & Postma, M. J. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01307-0 · Cited by 11
Rubinstein, S. M., Yang, P. C., Cowan, A. J., et al. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00122 · Cited by 10
“Several recent randomized controlled trials have demonstrated superior progression-free survival for three-drug combinations compared with two drug combinations in a variety of treatment settings.(16-18) Four-drug combinations are currently under active investigation.”
BackgroundTakamatsu, H., Iida, S., Shibayama, H., Shibayama, K., Yamazaki, H., & Suzuki, K. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02825-w · Cited by 10
Takamatsu, H. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02828-7 · Cited by 10
“[33] reported that the addition of daratumumab to a regimen of lenalidomide plus dexamethasone (DRd) significantly reduced the risk of disease progression or death in newly diagnosed ASCT-ineligible patients with MM.”
BackgroundKocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 11
“CLARION study (NCT01818752) investigated the addition of bortezomib versus carfilzomib to the melphalan/prednisone backbone [29].”
BackgroundImmunotherapy in multiple myeloma: when, where, and for who?
Verkleij, C. P. M., Korst, C. L. B. M., & van de Donk, N. W. C. J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000677 · Cited by 10
“In both studies patients with high-risk cytogenetic abnormalities experienced less benefit from daratumumab compared with standard risk patients [11].”
BackgroundResultInfluentialRichard, S., Jagannath, S., Cho, H. J., Parekh, S. S., Madduri, D., Richter, J. R., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1858790 · Cited by 11
Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye
Vaxman, I., & Gertz, M. A. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1873320 · Cited by 10
Rice, M. S., Naeger, S., & Singh, E. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00146-4 · Cited by 10
Sequencing of myeloma therapy: Finding the right path among many standards
Rajkumar, S. V. (2021) · Hematological Oncology · doi:10.1002/hon.2848 · Cited by 12
“In high‐risk transplant eligible patients with double hit MM or triple hit MM, I recommend addition of daratumumab to the standard VRd regimen (Dara‐VRd), or the daratumumab, bortezomib, thalidomide, and dexamethasone (Dara‐VTd) regimen.8 There is no significant benefit with carfilzomib, lenalidomide, and dexamethason…”
BackgroundInfluentialKnowing the unknowns in high risk multiple myeloma
Derman, B. A., Kosuri, S., & Jakubowiak, A. J. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100887 · Cited by 10
Geraldes, C., Neves, M. L., Chacim, S. P., & da Costa, F. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.817762 · Cited by 10
“In studies conducted in relapsed/refractory patients, the combination therapy of daratumumab plus lenalidomide and dexamethasone (DRd), and of daratumumab plus pomalidomide and dexamethasone (DPd), led to the highest rates of Grade 3/4 infections.”
BackgroundFirst report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
Leung, N., Chapman, J. A., & Bhatia, S. (2023) · eJHaem · doi:10.1002/jha2.772 · Cited by 10
Multiple myeloma: Current and future management in the aging population
Fotiou, D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.04.015 · Cited by 10
How I Manage Frontline Transplant-Ineligible Multiple Myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8956 · Cited by 11
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 11
Self-citationShibayama, H., Itagaki, M., Handa, H., Yokoyama, A., Saito, A., Kosugi, S., Ota, S., Yoshimitsu, M., Tanaka, Y., Kurahashi, S., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03754-8 · Cited by 10
Theves, F., Lahuna, C., Mahevas, T., Harel, S., Royer, B., Lemiale, V., Brignier, A., Parquet, N., Jachiet, M., Bouaziz, J., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20257 · Cited by 9
Jiang, H., Li, L., Guo, M., Li, M., Wu, H., Chen, X., Gao, M., Xu, Q., Mi, J. D., Cui, C., et al. (2024) · Hematology · doi:10.1080/16078454.2024.2399430 · Cited by 9
“Of the 1541 records found in the search, 10 RCTs (18 references) [20, 24, 28–43] that satisfied the inclusion and exclusion criteria were identified for meta-analysis (Figure 1).”
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Touzeau, C., Leleu, X. P., Tiab, M., Macro, M., Perrot, A., Gay, J., Chateleix, C., Moreau, S., Karlin, L., Jacquet, C., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.19978 · Cited by 10
Self-citationKannan, A., Jeffrey, K., Misbah, S., & Ramasamy, K. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101287 · Cited by 11
Bruins, W. S. C., Smits, F., Duetz, C., Groen, K., Korst, C. L. B. M., de Jonge, A. V., Verkleij, C. P. M., Rentenaar, R., Cosovic, M., Eken, M., et al. (2025) · Blood · doi:10.1182/blood.2025028587 · Cited by 13
Self-citationMohyuddin, G. R., Sigle, M., Chandrasekar, V. T., Aziz, M., Abdallah, A.-O. A., Shune, L. O., & McClune, B. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1772475 · Cited by 9
Joseph, N. S., Gupta, V. A., Wyman, S., Graiser, M., Kaufman, J. L., Almaula, D. K., Andrews, J., Hofmeister, C. C., Dhodapkar, M. V., Heffner, L. T., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.024 · Cited by 9
Osterhoff, G., Kreinest, M., Kuhnt, T., Pohlenz, C., Müller-Broich, J. D., Röllig, C., Teipel, R., Scheyerer, M. J., Schnake, K. J., Spiegl, U. J. A., et al. (2023) · Global Spine Journal · doi:10.1177/21925682221143732 · Cited by 9
Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282624 · Cited by 9
“With the success of RVd in NDMM, newer agents have been evaluated in this setting with Rd, including carfilzomib, 24 ixa-zomib, 25 daratumumab (DARA), 26 and elotuzumab.”
MethodSelf-citationZhao, J., Wu, M., Li, Z., Su, S., Wen, Y., Zhang, L., & Li, Y. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04020-7 · Cited by 10
“A higher incidence of neutropenia and pneumonia was observed in the daratumumab group [129].”
BackgroundDaratumumab subcutaneous formulation for the treatment of multiple myeloma
Paul, B. A., Hamadeh, I. S., Atrash, S., Bhutani, M., Voorhees, P. M., & Usmani, S. Z. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1806231 · Cited by 9
Self-citationMonoclonal antibodies as an addition to current myeloma therapy strategies
Jullien, M., Touzeau, C., & Moreau, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1837627 · Cited by 10
Self-citationKorst, C. L. B. M., & van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000161 · Cited by 9
New regimens and directions in the management of newly diagnosed multiple myeloma
Bal, S., Giri, S., Godby, K. N., & Costa, L. J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26080 · Cited by 9
“73) were significantly better in the Dara-RD arm.(12,14) An ongoing phase II study is also evaluating daratumumab in combination with ixazomib, lenalidomide, and”
BackgroundCook, G., Corso, A., Streetly, M. J., Mendeleeva, L. P., Ptushkin, V. V., Chan, E. S., Ukropec, J., Iraqi, W., Al-Akabawi, A., Pei, H., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-020-00137-x · Cited by 9
Minimal Residual Disease in Multiple Myeloma
Mina, R., Bonello, F., & Oliva, S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000519 · Cited by 9
“01.(6,7) Currently, MRD is also evaluated in most trials at relapse.”
BackgroundGenomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?
Botrugno, O. A., & Tonon, G. (2021) · Cancers · doi:10.3390/cancers14010025 · Cited by 9
18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma
Hemrom, A., Tupalli, A., Alavi, A. A., & Kumar, R. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.001 · Cited by 9
Steps towards a Multiple Myeloma Cure?
Gozzetti, A., & Bocchia, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091451 · Cited by 9
Newly diagnosed multiple myeloma: making sense of the menu
Costello, C. L. (2022) · Hematology · doi:10.1182/hematology.2022000404 · Cited by 11
Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
Huang, S.-X., Luo, P.-H., Wang, H.-L., Mo, D.-C., & Huang, J.-F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02665 · Cited by 9
Outcomes of COVID ‐19 in multiple myeloma patients treated with daratumumab
Jin, D., He, J., Wu, W., et al. (2023) · Cancer Science · doi:10.1111/cas.16001 · Cited by 9
Olin, R. L. (2019) · Blood · doi:10.1182/blood.2019001300 · Cited by 9
Antibody therapies for multiple myeloma
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., & Terpos, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1717464 · Cited by 9
Modern treatments and future directions for newly diagnosed multiple myeloma patients
Lu, S. X. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101151 · Cited by 10
New drugs in early development for treating multiple myeloma: all that glitters is not gold
Bertamini, L., Bonello, F., Boccadoro, M., & Bringhen, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1772753 · Cited by 9
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
Pasvolsky, O., Marcoux, C., Dai, J., Milton, D. R., Tanner, M. R., Syed, N., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.001 · Cited by 10
Self-citationCAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Yu, T., Jiao, J., & Wu, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499590 · Cited by 12
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 10
Cani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.003 · Cited by 8
Grant, S. J., & Lipe, B. C. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30470-5 · Cited by 8
Tang, W., Li, Y., Zou, Z., Cui, J., Wang, F., Zheng, Y., Hou, L., Pan, L., Xiang, B., Chang, H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5228 · Cited by 8
Brownlie, R. J., Kennedy, R., Wilson, E., Milanovic, M., Taylor, C., Wang, D., Davies, J. R., Owston, H. E., Adams, E. J., Stephenson, S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009044 · Cited by 8
“CD38-directed mAb therapy is often successfully used in the treatment of patients with RRMM(57,58) and in combination therapies for patients with newly diagnosed disease.(59) However, many patients cannot be treated effectively with CD38-directed therapy because of either low levels of CD38 expression on MM cells, a r…”
MethodLonial, S., Bowser, A. D., Chari, A., Costello, C. L., Krishnan, A. Y., & Usmani, S. Z. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.07.001 · Cited by 9
Self-citationBreaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Solimando, A. G., Krebs, M., Desantis, V., Marziliano, D., Caradonna, I. C., Morizio, A., Argentiero, A., Shahini, E., & Bittrich, M. (2023) · Biomedicines · doi:10.3390/biomedicines11072087 · Cited by 9
“%) as well as patients with negative minimal residual disease in this clinical trial (29% vs. 9%, 10 − 5 ) [119,120].”
BackgroundFabro, V. D., Giorgio, M. A. D., Leotta, V., Duminuco, A., Bellofiore, C., Markovic, U., Romano, A., Bulla, A., Pelle, A. C., Elia, F., et al. (2023) · Cancers · doi:10.3390/cancers15164036 · Cited by 8
“001), and the risk of disease progression or death was 44% lower in the D-Len/Dex group than in the Len/Dex group [11].”
BackgroundLi, P., Xu, B., Xu, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814097 · Cited by 8
“The lenalidomide-based treatment regimen has significantly enhanced the clinical prognosis of patients with both newly diagnosed multiple myeloma (NDMM) and relapsed and refractory multiple myeloma (RRMM) [2].”
BackgroundEndoplasmic reticulum stress and proteasome inhibitors in multiple myeloma – a room for improvement
Kubicki, T., Gil, L., & Dytfeld, D. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15896 · Cited by 8
Tabata, R., Sato, N., Yamauchi, N., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04525-9 · Cited by 8
Li, S., Li, J., Peng, L., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.05.015 · Cited by 8
LeBlanc, R., Mian, H. S., Reece, D. E., Masih‐Khan, E., Kardjadj, M., Jimenez-Zepeda, V. H., McCurdy, A. B. R., Song, K., Sébag, M., Louzada, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18172 · Cited by 8
Self-citationRecent advances in the management of older adults with newly diagnosed multiple myeloma in Japan
Suzuki, T., Maruyama, D., Iida, S., & Nagai, H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac111 · Cited by 8
“Treatment strategy for frail patients The clinical trials described above have established the standard therapies for older patients with NDMM. Applicability of the results of these trials to frail patients was evaluated in a supplemental study of the ALCYONE and MAIA trials.”
BackgroundResultInfluentialHuynh, L., Birsen, R., Mora, L., Couderc, A., Mitha, N., Farcet, A., Chebib, A., & Chaı̈bi, P. (2022) · Cancers · doi:10.3390/cancers14194741 · Cited by 8
“3 versus 4% in ALCYONE) times more frequent with daratumumab [5,7].”
BackgroundResultInfluentialHoller, M., Ihorst, G., Reinhardt, H., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281489 · Cited by 8
“Thrombocytopenia (%) 25 (10) 3 (4) 13 (9) 9 (28) 0.”
Feng, C., Chang, C.-W., Lien, Z., et al. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24891 · Cited by 8
Moscvin, M., Evans, B., & Bianchi, G. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.110 · Cited by 8
“Similarly, based on the MAIA trial, FDA approved Dara-Rd for non-transplant-eligible NDMM (median PFS of about 5 years) [183] .”
MethodOertel, M., Schlusemann, T., Shumilov, E., Reinartz, G., Bremer, A., Rehn, S., Lenz, G., Khandanpour, C., & Eich, H. T. (2023) · Cancers · doi:10.3390/cancers15112909 · Cited by 9
“Recently developed agents like daratumumab have not been considered in our analysis but may lead to new challenges in toxicity management [28].”
BackgroundBoutin, R., Lee, H., Guan, T. L., Nguyen, T. T., Huang, X. F., Waller, D. D., Lu, J., Chio, I. I. C., Michel, R. P., Sébag, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01271 · Cited by 8
Xu, W., Li, D., Sun, Y., Ran, X., Wang, B., Wu, W., Sheng, Z., & Liu, L. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13317 · Cited by 8
Kazandjian, D. G., Dew, A., & Hill, E. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101150 · Cited by 8
Multiple Myeloma in a Young Female Presenting with Neurological Symptoms
Lee, M. H., Zhang, X., Nguyen, V. N., & Hartley-Brown, M. A. (2020) · Case Reports in Hematology · doi:10.1155/2020/1375174 · Cited by 8
“3% in the control arm had evidence of minimal residual disease [34].”
BackgroundThe safety of current and emerging therapies for multiple myeloma
Nadeem, O., & Anderson, K. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733968 · Cited by 8
“Daratumumab is an IgG1 k anti-CD38 monoclonal antibody that is currently approved as monotherapy [48] and in various combination therapies in NDMM [8,49] and RRMM [20,42,50].”
BackgroundInfluentialJessee, J. K. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211058388 · Cited by 8
Wijnands, C., Karel, P. G. A., Gloerich, J., Armony, G., Tzasta, A., Angelino, C. M. D. K., Stéfano, L. D., Bonifay, V., Luider, T. M., VanDuijn, M. M., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010135 · Cited by 7
Raab, M. S., Weinhold, N., Kortüm, K. M., Krönke, J., Fenk, R. R., Weisel, K. C., Podola, L., Bertsch, U., Brobeil, A., Mersi, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04471-x · Cited by 8
Self-citationSweiss, K. I., Vemu, B., Hofmeister, C. C., Wenzler, E., Calip, G. S., Galvin, J. P., Mahmud, N., Rondelli, D., Johnson, J. J., & Patel, P. R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14308 · Cited by 6
“MM is characterized by a pattern of recurrent remissions and relapses and remains incurable despite numerous drug classes developed specifically for myeloma, e.g. immunomodulator drugs, proteasome inhibitors, CD38 antibodies, nuclear export inhibitors and chimeric antigen receptor T-cells.28,29 Despite significant pha…”
BackgroundInfluentialNawas, M. T., Sheng, Y., Huang, C., Andreadis, C. B., Martin, T. G., Wolf, J. L., Ai, W. Z., Kaplan, L. D., Mannis, G. N., Logan, A. C., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.09.027 · Cited by 6
Sun, Q., Li, X., Gu, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.776920 · Cited by 7
Côté, J. A., Kotb, R. R., Bergstrom, D. J., LeBlanc, R., Mian, H. S., Othman, I., & Louzada, M. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.016 · Cited by 9
Kikuchi, T., Tsukada, N., Kunisada, K., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03770-8 · Cited by 7
“Several phase 3 clinical trials have demonstrated the additional efficacy of daratumumab compared with that of the control arm in patients with newly diagnosed MM (NDMM) and in those with relapsed/refractory MM (RRMM) [1–6].”
Novellis, D. D., Fontana, R., Serio, B., Vaccaro, E., Guariglia, R., Morini, D., Rizzo, M., Giudice, V., & Selleri, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7402 · Cited by 7
Hansen, D. K., Gautam, S., Lafeuille, M., Rossi, C., Moore, B., Tardif‐Samson, A., Thompson‐Leduc, P., Fu, A. Z., Cortoos, A., Kaila, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70308 · Cited by 7
“…while the SWOG S0777 trial enrolled a mixed NDMM population including patients who were eligible for SCT but chose to defer or refuse treatment [13, 14]), that particular analysis [18] as well as other subsequent analyses have included only a portion of SWOG S0777 trial participants to improve…”
BackgroundMethodResult
Metadata
- Authors
- Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., & Usmani, S. Z.
- Affiliations
- Université de Lille (FR)
- Mayo Clinic (US)
- University of Southern Denmark (DK)
- The University of Texas MD Anderson Cancer Center (US)
- University of Calgary (CA)
- Karolinska University Hospital (SE)
- The University of Melbourne (AU)
- From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d’Hématologie, CHU de Toulouse–Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La...
- University of Alberta (CA)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- ORCID
- Facon, Thierry
- Kumar, Shaji
- Plesner, Torben
- Orlowski, Robert Z.
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
- Nahi, Hareth
- Hulin, Cyrille
- Quach, Hang
- Goldschmidt, Hartmut
- Perrot, Aurore
- Venner, Christopher P.
- Weisel, Katja
- Raje, Noopur
- Attal, Michel
- Macro, Margaret
- Frenzel, Laurent
- Leleu, Xavier
- Ahmadi, Tahamtan
- Chiu, Christopher
- Wang, Jianping
- Qi, Ming
- Usmani, Saad Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-30
- Volume
- 380
- Issue
- 22
- Pages
- 2104-2115
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10045721
- OpenAlex
- W2947874495
- Cited by
- 1,045
- References
- 32
- Citations by year
- 2026: 105 · 2025: 111 · 2024: 107 · 2023: 130 · 2022: 145 · 2021: 208 · 2020: 195 · 2019: 39
- FWCI
- 107.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton) (acceptedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- Janssen Research and Development (-)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- daratumumab, lenalidomide, dexamethasone, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, adverse events, autologous stem cell transplantation ineligibility, monoclonal antibody therapy, combination therapy, anemia, lymphopenia
- MeSH terms
- Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neutropenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
